Physicians have an intense 70-year history of enthusiasm, skepticism, fear, and reconciliation with albumin products since their market introduction in the late 1940s. Despite its cumbersome production method and costs, albumin became popular soon after its debut. Advances in its production technique, producing purer formulations with less prekallikrein activators, turned it into a compound with few immediate adverse reactions that appeared to be safe. However, the most recent turbulent episodes of albumin use (still known by most critical care physicians) start with the notorious meta-analysis suggesting harm, passes through a redemption clinical trial, and lands on more recent studies that may point to a specific direction, but yet provide no conclusive data.

Read More